Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs and glucocorticoids

被引:0
|
作者
Koh, Eun-Mi [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul, South Korea
来源
关键词
Rheumatoid arthritis; NSAIDs; DMARDs; Glucocorticoids; RECOMMENDATIONS; MANAGEMENT;
D O I
10.5124/jkma.2010.53.10.871
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The medical treatment of rheumatoid arthritis has been dramatically improved with the advances of newer disease-modifying antirheumatic drugs (DMARDs) and biologic agents during previous decades. To prevent joint damage, it is essential to start DMARD treatment early, especially within the first 3 months after diagnosis. Tight control of disease activity, and the thorough monitoring of the treatment's efficacy and the side effects of medications are also important. Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually used to control pain and swelling of the joints. However, these drugs cannot alter the disease course of rheumatoid arthritis. It is therefore necessary to introduce DMARDs at the beginning of treatment, and, after achieving the effect of DMARDs, NSAIDs should be tapered as soon as possible. The main treatment should be DMARDs, which must be used wisely and appropriately. It is also important to adjust DMARD therapy during the course of treatment according to disease activity. Glucocorticoids have potent anti-inflammatory effects and can control inflammation dramatically. However, because of the diverse and serious side effects of glucocorticoids, the usage of glucocorticoids should be limited to low-dose oral therapy or intra-articular injection, unless otherwise indicated. Along with biologics, there are now various weapons available against rheumatoid arthritis, and it can be treated much more effectively than before.
引用
收藏
页码:871 / 879
页数:9
相关论文
共 50 条
  • [31] German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs
    Katinka Albrecht
    Klaus Krüger
    Jürgen Wollenhaupt
    Rieke Alten
    Marina Backhaus
    Christoph Baerwald
    Wolfgang Bolten
    Jürgen Braun
    Harald Burkhardt
    Gerd R. Burmester
    Markus Gaubitz
    Angela Gause
    Erika Gromnica-Ihle
    Herbert Kellner
    Jens Kuipers
    Andreas Krause
    Hans-Martin Lorenz
    Bernhard Manger
    Hubert Nüßlein
    Hans-Georg Pott
    Andrea Rubbert-Roth
    Matthias Schneider
    Christof Specker
    Hendrik Schulze-Koops
    Hans-Peter Tony
    Siegfried Wassenberg
    Ulf Müller-Ladner
    Rheumatology International, 2014, 34 : 1 - 9
  • [32] Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis
    Rath, T.
    Sander, O.
    Rubbert, A.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 657 - 663
  • [33] Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis
    Hider, SL
    Bruce, IN
    Silman, AJ
    Symmons, DPM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (01) : 6 - 10
  • [34] German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs
    Albrecht, Katinka t
    Krueger, Klaus
    Wollenhaupt, Juergen
    Alten, Rieke
    Backhaus, Marina
    Baerwald, Christoph
    Bolten, Wolfgang
    Braun, Juergen
    Burkhardt, Harald
    Burmester, Gerd R.
    Gaubitz, Markus
    Gause, Angela
    Gromnica-Ihle, Erika
    Kellner, Herbert
    Kuipers, Jens
    Krause, Andreas
    Lorenz, Hans-Martin
    Manger, Bernhard
    Nuesslein, Hubert
    Pott, Hans-Georg
    Rubbert-Roth, Andrea
    Schneider, Matthias
    Specker, Christof
    Schulze-Koops, Hendrik
    Tony, Hans-Peter
    Wassenberg, Siegfried
    Mueller-Ladner, Ulf
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (01) : 1 - 9
  • [35] TOXICITY PROFILES OF DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS
    SINGH, G
    FRIES, JF
    WILLIAMS, CA
    ZATARAIN, E
    SPITZ, P
    BLOCH, DA
    JOURNAL OF RHEUMATOLOGY, 1991, 18 (02) : 188 - 194
  • [36] Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
    Manathip Osiri
    Pirom Kamolratanakul
    Andreas Maetzel
    Peter Tugwell
    Rheumatology International, 2007, 27 : 1063 - 1069
  • [37] Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis
    Martinez-Mugica, Cristina
    Salgueiro, Esther
    FARMACIA HOSPITALARIA, 2022, 46 (01) : 15 - 20
  • [39] Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
    Osiri, Manathip
    Kamolratanakul, Pirom
    Maetzel, Andreas
    Tugwell, Peter
    RHEUMATOLOGY INTERNATIONAL, 2007, 27 (11) : 1063 - 1069
  • [40] Nonsteroidal anti-inflammatory drugs
    Gotzsche, PC
    AMERICAN FAMILY PHYSICIAN, 2006, 73 (03) : 507 - 508